John M Bennett
Overview
Explore the profile of John M Bennett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
8916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, et al.
J Natl Compr Canc Netw
. 2025 Mar;
23(3):66-75.
PMID: 40073835
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has...
2.
Gisriel S, Aakash F, Bennett J, Hasserjian R, Loghavi S, DeZern A, et al.
Arch Pathol Lab Med
. 2025 Mar;
PMID: 40059041
Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation...
3.
Summerer I, Walter W, Meggendorfer M, Haferlach T, Dicker F, Hutter S, et al.
Blood Cancer J
. 2025 Mar;
15(1):29.
PMID: 40032819
No abstract available.
4.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
5.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
6.
Bennett J, Narwal S, Kabeche S, Abegg D, Thathy V, Hackett F, et al.
Cell Chem Biol
. 2024 Aug;
31(9):1714-1728.e10.
PMID: 39137783
Malaria, caused by Plasmodium falciparum, remains a significant health burden. One major barrier for developing antimalarial drugs is the ability of the parasite to rapidly generate resistance. We previously demonstrated...
7.
Bennett J, Narwal S, Kabeche S, Abegg D, Hackett F, Yeo T, et al.
bioRxiv
. 2024 Jan;
PMID: 38260474
Malaria, caused by remains a significant health burden. A barrier for developing anti-malarial drugs is the ability of the parasite to rapidly generate resistance. We demonstrated that Salinipostin A (SalA),...
8.
El Hussein S, ODywer K, Bennett J
EJHaem
. 2023 Nov;
4(4):1179-1181.
PMID: 38024631
No abstract available.
9.
Bennett J, Ward K, Muir R, Kabeche S, Yoo E, Yeo T, et al.
ACS Infect Dis
. 2023 Sep;
9(10):2036-2047.
PMID: 37712594
The proteasome is a promising antimalarial drug target due to its essential role in all parasite lifecycle stages. Furthermore, proteasome inhibitors have synergistic effects when combined with current first-line artemisinin...
10.
Stahl M, Bewersdorf J, Xie Z, Della Porta M, Komrokji R, Xu M, et al.
Blood Rev
. 2023 Sep;
62:101128.
PMID: 37704469
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we...